Zelira Therapeutics (G1G) Income Statement
Zelira Therapeutics Income Statement
Last quarter (Q4 2025), Zelira Therapeutics's total revenue was $1.00, a decrease of 100.00% from the same quarter last year. In Q4, Zelira Therapeutics's net income was $-1.22M. See Zelira Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| $ 656.00 | $ 94.95K | $ 301.12K | $ 1.54M | $ 663.32K | |
| $ -802.95K | $ 10.28K | $ -3.22M | $ -5.72M | $ -39.16K | |
| $ 3.15M | $ 5.95M | $ 6.17M | $ 7.70M | $ 9.61M | |
| Depreciation and Amortization | $ 270.48K | $ 479.04K | $ 545.22K | $ 588.54K | $ 474.25K |
| $ -4.05M | $ -36.44M | $ -6.79M | $ -13.06M | $ -9.41M | |
| $ -3.95M | $ -5.94M | $ -7.41M | $ -13.41M | $ -9.65M | |
| $ 102.52K | $ -30.80M | $ 1.29K | $ -290.82K | $ -275.31K | |
| $ -3.85M | $ -36.74M | $ -7.41M | $ -13.71M | $ -9.93M | |
| $ -3.63M | $ -36.57M | $ -5.57M | $ -11.95M | $ -8.55M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.32 | $ -3.22 | $ -0.55 | $ -1.49 | $ -1.29 |
| Diluted EPS | $ -0.32 | $ -3.22 | $ -0.55 | $ -1.49 | $ -1.29 |
| Weighted Average Shares Outstanding | 11.48M | 11.35M | 10.07M | 8.04M | 6.63M |
| Weighted Average Shares Outstanding (Diluted) | 11.48M | 11.35M | 10.07M | 8.04M | 6.63M |
Currency in AUD
